This site is intended for healthcare professionals
Drug information

Dolpin

POM
Read time: 26 mins
Last updated: 06 May 2020
Published: 24 Jul 2020

4.1 Therapeutic indications

Adult patients aged 18 years and above

• Treatment of schizophrenia and schizoaffective disorder.

• Acute treatment of delirium when non-pharmacological treatments have failed.

• Treatment of moderate to severe manic episodes associated with bipolar I disorder.

• Treatment of acute psychomotor agitation associated with psychotic disorder or manic episodes of bipolar I disorder.

• Treatment of persistent aggression and psychotic symptoms in patients with moderate to severe Alzheimer's dementia and vascular dementia when non-pharmacological treatments have failed and when there is a risk of harm to self or others.

• Treatment of tic disorders, including Tourette's syndrome, in patients with severe impairment after educational, psychological and other pharmacological treatments have failed.

• Treatment of mild to moderate chorea in Huntington's disease, when other medicinal products are ineffective or not tolerated.

Paediatric patients

Treatment of:

• Schizophrenia in adolescents aged 13 to 17 years when other pharmacological treatments have failed or are not tolerated.

• Persistent, severe aggression in children and adolescents aged 6 to 17 years with autism or pervasive developmental disorders, when other treatments have failed or are not tolerated.

• Tic disorders, including Tourette's syndrome, in children and adolescents aged 10 to 17 years with severe impairment after educational, psychological and other pharmacological treatments have failed.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

 

 

Disclaimer

The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC (www.medicines.org.uk/emc/). Medthority offers the whole library of SPC documents from eMC.

Medthority will not be held liable for explicit or implicit errors, or missing data.

Reporting of suspected adverse reactions 

Drug Licencing

Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).